• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Case Study Identifies Rare Genomic Profile in Microgranular Promyelocytic Leukemia

by
November 20, 2026
in Health
Reading Time: 5 mins read
0
Case Study Identifies Rare Genomic Profile in Microgranular Promyelocytic Leukemia

Case Study Identifies Rare Genomic Profile in Microgranular Promyelocytic Leukemia

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A genomically defined case report has documented the clinical course and diagnostic evaluation of a young patient presenting with microgranular acute promyelocytic leukemia that harbored both a concurrent FLT3 tyrosine kinase domain mutation and high-level MYC amplification. Acute promyelocytic leukemia is driven by the pathognomonic PML::RARA fusion oncoprotein arising from the balanced translocation t(15;17)(q24;q21), which arrests myeloid differentiation at the promyelocyte stage through epigenetic repression of retinoic acid target genes. Although acute promyelocytic leukemia has evolved into a highly curable malignancy with contemporary complete remission rates exceeding ninety percent when targeted with all-trans retinoic acid and arsenic trioxide, the microgranular variant accounts for approximately twenty to twenty-five percent of presentations and frequently poses diagnostic challenges. In the newly reported case, clinicians identified a cooperative genomic constellation involving an FLT3 tyrosine kinase domain point mutation at codon D835 alongside high-level copy-number amplification of the MYC oncogene, expanding the recognized molecular spectrum of this morphological subtype.

The patient, a thirty-five-year-old woman with no documented prior medical history, presented to an emergency facility following a one-week duration of progressive fatigue, high-grade fever, spontaneous gingival bleeding, and extensive ecchymoses across her body, without concurrent weight loss, night sweats, or bone pain. Clinical evaluation documented an Eastern Cooperative Oncology Group performance status of 3. On initial physical examination, the patient appeared lethargic, pale, and ill, with a recorded body temperature of 38.5 degrees Celsius, tachycardia characterized by a heart rate of 115 beats per minute, and normal blood pressure readings. Specific physical findings demonstrated active oral mucosal hemorrhage, palatal petechiae, and widespread ecchymoses distributed over her trunk and extremities, while manual palpation revealed no evidence of hepatosplenomegaly or peripheral lymphadenopathy.

Urgent baseline laboratory investigations revealed profound cytopenias accompanied by severe coagulopathy diagnostic of overt disseminated intravascular coagulation. The patient’s complete blood count demonstrated a hemoglobin concentration of 7.1 grams per deciliter, a markedly reduced white blood cell count of 1.8 times 10 to the ninth power per liter, and severe thrombocytopenia with a platelet count of 19 times 10 to the ninth power per liter. Coagulation profiling confirmed a consumptive state, showing severe hypofibrinogenemia with a plasma fibrinogen concentration of 98 milligrams per deciliter, a prothrombin time international normalized ratio of 1.7, and markedly elevated D-dimer concentrations exceeding 20,000 nanograms per milliliter. These acute hematologic disturbances reflected an active consumptive coagulopathy that required immediate supportive transfusion management alongside targeted antileukemic intervention.

Microscopic evaluation of the peripheral blood smear proved critically informative yet diagnostically misleading, creating immediate diagnostic ambiguity. The circulating blood contained twenty to twenty-five percent atypical mononuclear cells that displayed folded, bilobed or reniform nuclei and a conspicuous paucity of fine cytoplasmic granules, morphologically mimicking the monoblasts characteristic of acute monoblastic leukemia, French-American-British subtype M5. Furthermore, peripheral blood films demonstrated marked red blood cell fragmentation, showing numerous schistocytes exceeding fifty per high-power field. This prominent schistocytosis suggested secondary microangiopathic changes and initially raised clinical consideration of a thrombotic microangiopathy-like process occurring alongside acute leukemia.

Because microgranular morphology can delay the administration of time-critical differentiating agents, immediate bone marrow aspiration and core biopsy were executed alongside rapid immunophenotyping. The bone marrow specimen was markedly hypercellular at ninety percent cellularity and largely replaced by a monomorphic infiltration of atypical promyelocytes displaying bilobed nuclear contours. Urgent flow cytometric analysis established an immunophenotypic signature characteristic of acute promyelocytic leukemia, demonstrating bright CD33 expression, positive CD13 expression, retained CD117 expression, and a complete absence of CD34, HLA-DR, and CD14. This rapid diagnostic immunophenotyping resolved the morphological ambiguity within hours, confirming microgranular acute promyelocytic leukemia and distinguishing it from acute monocytic leukemia, thereby enabling the prompt initiation of targeted differentiating therapy.

Comprehensive cytogenetic and molecular analyses definitively confirmed the underlying leukemia biology and characterized its genomic architecture. Conventional metaphase cytogenetic analysis demonstrated a 46,XX female karyotype containing the classical translocation t(15;17)(q24;q21) in all analyzed metaphases. Interphase fluorescence in situ hybridization verified the presence of PML::RARA fusion signals, while reverse-transcription polymerase chain reaction testing detected the short bcr-3 isoform of the PML::RARA fusion transcript, an isoform recognized to associate with heightened proliferative kinetics. These findings established the definitive molecular diagnosis and supported the multidisciplinary planning of subsequent risk-adapted therapeutic strategies.

Targeted next-generation sequencing using a validated 54-gene myeloid panel on an Illumina MiSeq platform, executed with mean sequencing coverage exceeding 500-fold, identified an FLT3 tyrosine kinase domain point mutation, c.2503G to T (p.D835Y), at a variant allele frequency of forty-two percent. In addition, locus-specific fluorescence in situ hybridization targeting the 8q24 locus and metaphase cytogenetic analysis demonstrated high-level MYC amplification, defined by signal clusters and duplicated signals yielding eight or more copies per cell across more than twenty percent of analyzed abnormal cells. A systematic literature search across PubMed, Scopus, and Google Scholar through May 2026 confirmed that the concurrent combination of an FLT3-TKD mutation and high-level MYC copy-number gain had not been previously reported in microgranular acute promyelocytic leukemia.

Antileukemic therapy was initiated on day one with oral all-trans retinoic acid at forty-five milligrams per square meter daily divided into two doses, supported by platelet transfusions and cryoprecipitate to correct the consumptive coagulopathy. Although the patient presented with initial leukopenia, rapid treatment-emergent leukocytosis developed by day three of all-trans retinoic acid therapy, with the white blood cell count escalating sharply to peak at 25 times 10 to the ninth power per liter. Clinicians preemptively managed this proliferation by promptly adding intravenous arsenic trioxide at 0.15 milligrams per kilogram daily and concurrent dexamethasone at ten milligrams twice daily for three days, achieving rapid symptomatic stabilization and normalization of circulating leukocyte counts.

To mitigate the long-term cardiotoxicity associated with traditional anthracycline therapy in a young adult, the multidisciplinary clinical team formulated an intensified, anthracycline-sparing induction regimen. Given the patient’s strong leukemic blast CD33 expression, the proliferative bcr-3 transcript, the FLT3-TKD mutation, and high-level MYC amplification, a single dose of the antibody-drug conjugate gemtuzumab ozogamicin was administered at three milligrams per square meter on day five. The patient tolerated induction therapy well, achieving complete morphological remission with normal trilineage hematopoiesis on day twenty-eight bone marrow evaluation. She subsequently completed consolidation consisting of four cycles of all-trans retinoic acid and arsenic trioxide. Quantitative serial monitoring demonstrated rapid logarithmic clearance of PML::RARA with a transcript half-life of 3.2 days, disappearance of the FLT3-TKD mutation to zero percent variant allele frequency, and sustained complete molecular remission with undetectable minimal residual disease at twelve months of follow-up.

In evaluating the diagnostic and therapeutic aspects of the case, the authors emphasized that the prominent schistocytosis and microangiopathic features were secondary to severe leukemia-associated disseminated intravascular coagulation rather than an independent primary thrombotic microangiopathy, as the hematologic disturbances fully resolved following antileukemic therapy without dedicated ADAMTS13 testing. Although gemtuzumab ozogamicin provided a viable anthracycline-free induction alternative in this setting, the authors explicitly noted that the limited availability of this agent in many healthcare facilities may constrain broader clinical replication, where anthracyclines such as daunorubicin remain standard. Furthermore, because this report details observations from a single patient monitored over twelve months, the clinical and biological significance of concurrent FLT3-TKD mutations and MYC amplification remains hypothesis-generating, and no definitive causal conclusions regarding treatment efficacy or prognostic impact can be established without validation in larger patient cohorts.

Subject of Research: Microgranular acute promyelocytic leukemia with concurrent FLT3-TKD mutation and MYC amplification

Article Title: Microgranular acute promyelocytic leukemia with concurrent FLT3-TKD mutation and MYC amplification: expanding the genomic spectrum and guiding personalized therapy

Article References: VatanParast, Y. (2026). Microgranular acute promyelocytic leukemia with concurrent FLT3-TKD mutation and MYC amplification: expanding the genomic spectrum and guiding personalized therapy. Journal of Rare Diseases, 5(1), Article 74. https://doi.org/10.1007/s44162-026-00217-y

Image Credits: AI Generated

DOI: 10.1007/s44162-026-00217-y

Keywords: acute promyelocytic leukemia, microgranular variant, FLT3-TKD mutation, MYC amplification, PML::RARA fusion, bcr-3 isoform, all-trans retinoic acid, arsenic trioxide, gemtuzumab ozogamicin, disseminated intravascular coagulation, thrombotic microangiopathy, next-generation sequencing, flow cytometry, fluorescence in situ hybridization, anthracycline-sparing therapy, treatment-emergent leukocytosis, complete molecular remission

News Source: Nathaniel Bowman. (November 20, 2026). Case Study Identifies Rare Genomic Profile in Microgranular Promyelocytic Leukemia. Scienmag.

Tags: acute promyelocytic leukemiaall-trans retinoic acidanthracycline-sparing therapyarsenic trioxidebcr-3 isoformcomplete molecular remissiondisseminated intravascular coagulationflow cytometryFLT3-TKD mutationfluorescence in situ hybridizationgemtuzumab ozogamicinmicrogranular variantMYC amplificationnext-generation sequencingPML::RARA fusionthrombotic microangiopathytreatment-emergent leukocytosis
Share12Tweet7Share2ShareShareShare1

Related Posts

Novel Gallium-68 Molecular Imaging Tracks Active Heart Fibrosis in Anderson–Fabry Disease

Novel Gallium-68 Molecular Imaging Tracks Active Heart Fibrosis in Anderson–Fabry Disease

November 20, 2026
Poor Sleep Quality Doubled and Linked to Pandemic Stress in Balkan Study

Poor Sleep Quality Doubled and Linked to Pandemic Stress in Balkan Study

November 20, 2026

Hypercoagulable States Linked to Higher Complication Risks in Cervical Spinal Fusion

November 20, 2026

Sociodemographic Factors Influence Migraine Burden and Prescription Treatment Access in Japan

November 20, 2026

POPULAR NEWS

  • Evidence on Glucose-Based ICU Fluids and Blood Sugar Control Remains Inconclusive

    Evidence on Glucose-Based ICU Fluids and Blood Sugar Control Remains Inconclusive

    29 shares
    Share 12 Tweet 7
  • DNA Computing and Bio-Robotics Revolutionize Biological Data Storage and Automation

    29 shares
    Share 12 Tweet 7
  • Multi-Stream Vision System Evaluates Classroom Teaching Behaviors With High Accuracy

    29 shares
    Share 12 Tweet 7
  • Five Clinicoradiological Markers Predict Progression-Free Survival in Advanced EGFR-Mutant Lung Adenocarcinoma

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Novel Gallium-68 Molecular Imaging Tracks Active Heart Fibrosis in Anderson–Fabry Disease

Bacterial Protective Protein Family Shields Cells During Natural Drug Biosynthesis

Poor Sleep Quality Doubled and Linked to Pandemic Stress in Balkan Study

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.